Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2005;14(4):449–462. doi: 10.1007/s11248-005-5697-3

Risk analysis for plant-made vaccines

Dwayne D Kirk 1,✉, Kim McIntosh 1, Amanda M Walmsley 1, Robert K D Peterson 2
PMCID: PMC7089354  PMID: 16201411

Abstract

The production of vaccines in transgenic plants was first proposed in 1990 however no product has yet reached commercialization. There are several risks during the production and delivery stages of this technology, with potential impact on the environment and on human health. Risks to the environment include gene transfer and exposure to antigens or selectable marker proteins. Risks to human health include oral tolerance, allergenicity, inconsistent dosage, worker exposure and unintended exposure to antigens or selectable marker proteins in the food chain. These risks are controllable through appropriate regulatory measures at all stages of production and distribution of a potential plant-made vaccine. Successful use of this technology is highly dependant on stewardship and active risk management by the developers of this technology, and through quality standards for production, which will be set by regulatory agencies. Regulatory agencies can also negatively affect the future viability of this technology by requiring that all risks must be controlled, or by applying conventional regulations which are overly cumbersome for a plant production and oral delivery system. The value of new or replacement vaccines produced in plant cells and delivered orally must be considered alongside the probability and severity of potential risks in their production and use, and the cost of not deploying this technology – the risk of continuing with the status quo alternative.

Keywords: edible vaccine, regulation, risk, transgenic plant

References

  1. Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol. 1998;16:934–938. doi: 10.1038/nbt1098-934. [DOI] [PubMed] [Google Scholar]
  2. Barone KS, Tolarova DD, Ormsby I, Doetschman T, Michael JG. Induction of oral tolerance in TGF-beta 1 null mice. J Immunol. 1998;161:154–160. [PubMed] [Google Scholar]
  3. Carrillo C, Wigdorovitz A, Oliveros PI, Zamorano AM, Sadir AM, Salinas GJ, Escribano JM, Borca MV. Protective immune respon to foot-and-mouth disease virus with VP1 expressed in transgenic plants. J Virol. 1998;72:1688–1690. doi: 10.1128/jvi.72.2.1688-1690.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Castanon S, Marin MS, Martin-Alonso JM, Boga JA, Casais R, Humara JM, Ordas RJ, Parra F. Immunization with potato plants expressing VP60 protein protects against rabbit hemorrhagic disease virus. J Virol. 1999;73:4452–4455. doi: 10.1128/jvi.73.5.4452-4455.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Castanon S, Martin-Alonso JM, Marin MS, Boga JA, Alonso P, Parra F, Ordas R. The effect of the promoter on expression of VP60 gene from rabbit hemorrhagic disease virus in potato plants. Plant Sci. 2002;162:87–95. doi: 10.1016/S0168-9452(01)00535-0. [DOI] [Google Scholar]
  6. Center for Food Safety and Nutrition (1994) FDA BACKGROUNDER: Biotechnology of Food. United States Food and Drug Administration. BG 94-4. May 18, 1994. http://www.cfsan.fda.gov/~lrd/biotechn.html, Last accessed 24 March 2005.
  7. Conko G. Safety, risk and the precautionary principle: rethinking precautionary approaches to the regulation of transgenic plants. Transgenic Res. 2003;12:639–647. doi: 10.1023/B:TRAG.0000005157.45046.8e. [DOI] [PubMed] [Google Scholar]
  8. Curtiss R., 3rd Genetically modified plants for use as oral immunogens. Mucosal Immunology Update. 1999;7:10–12. [Google Scholar]
  9. Curtiss R, 3rd and Cardineau GA (1990) Oral immunization by transgenic plants. World Patent Application WO 90/02484. Washington University (Assignee)..
  10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003;22:151–185. doi: 10.1016/S0167-6296(02)00126-1. [DOI] [PubMed] [Google Scholar]
  11. Fujihashi K, Dohi T, Kweon MN, McGhee JR, Koga T, Cooper MD, Tonegawa S, Kiyono H. gammadelta T cells regulate mucosally induced tolerance in a dose-dependent fashion. Int Immunol. 1999;11:1907–1916. doi: 10.1093/intimm/11.12.1907. [DOI] [PubMed] [Google Scholar]
  12. Ghosh S, Malhotra P, Lalitha PV, Guha-Mukherjee S, Chauhan VS. Expression of Plasmodium falciparum C-terminal region of merozoite surface protein (PfMSP119), a potential malaria vaccine candidate, in tobacco. Plant Sci. 2002;162:335–343. doi: 10.1016/S0168-9452(01)00555-6. [DOI] [Google Scholar]
  13. Goklany I. Precaution without perversity: a comprehensive application of the precautionary principle to genetically modified crops. Biotechnol Law Rep. 2001a;20:377–396. doi: 10.1089/073003101750297212. [DOI] [Google Scholar]
  14. Goklany I. The Precautionary Principle: A Critical Appraisal of Environmental Risk Assessment. Washington, DC: Cato Institute; 2001b. [Google Scholar]
  15. Gomez N, Wigdorovitz A, Castanon S, Gil F, Ordas R, Borca MV, Escribano JM. Oral immunogenicity of the plant derived spike protein from swine-transmissible gastroenteritis coronavirus. Arch Virol. 2000;145:1725–1732. doi: 10.1007/s007050070087. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Haq TA, Mason HS, Clements JD, Arntzen CJ. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science. 1995;268:714–716. doi: 10.1126/science.7732379. [DOI] [PubMed] [Google Scholar]
  17. Howard JA, Donnelly KC. A quantitative safety assessment model for transgenic protein products produced in agricultural crops. J Agr Environ Ethics. 2004;17:545–558. doi: 10.1007/s10806-004-1470-5. [DOI] [Google Scholar]
  18. Jaffe G. Regulating transgenic crops: a comparative analysis of different regulatory processes. Transgenic Res. 2004;13:5–19. doi: 10.1023/B:TRAG.0000017198.80801.fb. [DOI] [PubMed] [Google Scholar]
  19. Kapusta J, Modelska A, Figlerowicz M, Pniewski T, Letellier M, Lisowa O, Yusibov V, Koprowski H, Plucienniczak A, Legocki AB. A plant-derived edible vaccine against hepatitis B virus. FASEB J. 1999;13:1796–1799. doi: 10.1096/fasebj.13.13.1796. [DOI] [PubMed] [Google Scholar]
  20. Kirk DD, Rempel R, Pinkhasov J, Walmsley AM. Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines. Expert Opin Biol Ther. 2004;4:947–958. doi: 10.1517/14712598.4.6.947. [DOI] [PubMed] [Google Scholar]
  21. Kirk DD, Vonhof WM, Eibner J, Mason HS, and Zhang X (2003) Model production of a potent plant-made vaccine. NFID Sixth annual conference on vaccine research, Arlington, VA, May 5–7.
  22. Kirk DD, Webb SR. The next 15 years: taking plant-made vaccines beyond proof of concept. Immunol Cell Biol. 2005;83:248–256. doi: 10.1111/j.1440-1711.2005.01340.x. [DOI] [PubMed] [Google Scholar]
  23. Lightman A, Sarewitz D, Desser C, editors. Living with the Genie: Essays on Technology and the Quest for Human Mastery. Washington, D.C: Island Press; 2003. [Google Scholar]
  24. Liu L, Kuchroo VK, Weiner HL. B7.2 (CD86) but not B7.1 (CD80) costimulation is required for the induction of low dose oral tolerance. J Immunol. 1999;163:2284–2290. [PubMed] [Google Scholar]
  25. Ma S, Huang Y, Yin Z, Menassa R, Brandle JE, Jevnikar AM. Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc Natl Acad Sci USA. 2004;101:5680–5685. doi: 10.1073/pnas.0307420101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Ma SW, Zhao DL, Yin ZQ, Mukherjee R, Singh B, Qin HY, Stiller CR, Jevnikar AM. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat Med. 1997;3:793–796. doi: 10.1038/nm0797-793. [DOI] [PubMed] [Google Scholar]
  27. Mason HS, Haq TA, Clements JD, Arntzen CJ. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine. 1998;16:1336–1343. doi: 10.1016/S0264-410X(98)80020-0. [DOI] [PubMed] [Google Scholar]
  28. Mason HS, Lam DM, Arntzen CJ. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci USA. 1992;89:11745–11749. doi: 10.1073/pnas.89.24.11745. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Peterson RKD, (2002). How bad times how often: Risk as science. Agbiosafety. University of Nebraska-Lincoln. http://agbiosafety.unl.edu/riskasscience.shtml, Last accessed 24 March 2005.
  30. Peterson RKD, Arntzen CJ. On risk and plant-based biopharmaceuticals. Trends Biotechnol. 2004;22:64–66. doi: 10.1016/j.tibtech.2003.11.007. [DOI] [PubMed] [Google Scholar]
  31. Prakash CS. Edible vaccines and antibody producing plants. Biotechnol Dev Monit. 1996;27:10–13. [Google Scholar]
  32. Ratliff A. Biotechnology and pharmaceutical R&D and licensing trends: You pays your money and takes your chances. J Commercial Biotechnol. 2003;10:54–59. [Google Scholar]
  33. Rigano MM, Alvarez ML, Pinkhasov J, Jin Y, Sala F, Arntzen CJ, Walmsley AM. Production of a fusion protein consisting of the enterotoxigenic Escherichia coli heat-labile toxin B subunit and a tuberculosis antigen in Arabidopsis thaliana. Plant Cell Rep. 2004;22:502–508. doi: 10.1007/s00299-003-0718-2. [DOI] [PubMed] [Google Scholar]
  34. Presidential/Congressional Commission on Risk Assessment and Risk Management (1997) Risk Assessment and Risk Management in Regulatory Decision-Making. Final Report, Volume 2.
  35. Tackaberry ES, Prior F, Bell M, Tocchi M, Porter S, Mehic J, Ganz PR, Sardana R, Altosaar I, Dudani A. Increased yield of heterologous viral glycoprotein in the seeds of homozygous transgenic tobacco plants cultivated underground. Genome. 2003;46:521–526. doi: 10.1139/g03-008. [DOI] [PubMed] [Google Scholar]
  36. Tacket CO, Clements JD, Wasserman SS and Streatfield SJ (2003) Immunogenicity of a recombinant bacterial antigen delivered in transgenic corn. In NFID sixth annual conference on vaccine research, Arlington, VA, May 5–7.
  37. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, Arntzen CJ. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med. 1998;4:607–609. doi: 10.1038/nm0598-607. [DOI] [PubMed] [Google Scholar]
  38. Tacket CO, Mason HS, Losonsky G, Estes MK, Levine MM, Arntzen CJ. Human immune responses to a novel norwalk virus vaccine delivered in transgenic potatoes. J Infect Dis. 2000;182:302–305. doi: 10.1086/315653. [DOI] [PubMed] [Google Scholar]
  39. Tacket CO, Pasetti MF, Edelman R, Howard JA, Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine. 2004;22:4385–4389. doi: 10.1016/j.vaccine.2004.01.073. [DOI] [PubMed] [Google Scholar]
  40. Thanavala Y, Mahoney M, Pal S, Scott A, Richter L, Natarajan N, Goodwin P, Arntzen CJ, Mason HS. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci USA. 2005;102:3378–3382. doi: 10.1073/pnas.0409899102. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Twyman RM, Schillberg S, Fischer R. Transgenic plants in the biopharmaceutical market. Expert Opin Emerg Drugs. 2005;10:185–218. doi: 10.1517/14728214.10.1.185. [DOI] [PubMed] [Google Scholar]
  42. USDA–APHIS (2004) Transcript of Agriculture Secretary Ann M. Veneman’s remarks regarding Biotechnology Regulations. Washington, D.C. January 22, 2004. http://www. aphis.usda.gov/lpa/issues/biotechcomp/Transcript_of_Biotech _7DB94.doc, Last accessed 24 March 2005.
  43. Walmsley AM, Alvarez ML, Jin Y, Kirk DD, Lee SM, Pinkhasov J, Rigano MM, Arntzen CJ, Mason HS. Expression of the B subunit of Escherichia coli heat-labile enterotoxin as a fusion protein in transgenic tomato. Plant Cell Rep. 2003a;21:1020–1026. doi: 10.1007/s00299-003-0619-4. [DOI] [PubMed] [Google Scholar]
  44. Walmsley AM, Rowland L, Kirk DD, Miller TJ and Mason HS (2003b) Efficacy of an edible, plantderived immunocontraceptive vaccine in mice and voles. In NFID Sixth annual conference on vaccine research, Arlington, VA, May 5–7.
  45. Yu J, Langridge WH. A plant-based multicomponent vaccine protects mice from enteric diseases. Nat Biotechnol. 2001;19:548–552. doi: 10.1038/89297. [DOI] [PubMed] [Google Scholar]
  46. Yusibov V, Hooper DC, Spitsin SV, Fleysh N, Kean RB, Mikheeva T, Deka D, Karasev A, Cox S, Randall J, Koprowski H. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine. 2002;20:3155–3164. doi: 10.1016/S0264-410X(02)00260-8. [DOI] [PubMed] [Google Scholar]

Articles from Transgenic Research are provided here courtesy of Nature Publishing Group

RESOURCES